PetCaseFinder

Peer-reviewed veterinary case report

TRAF3 and POT1 gene mutations found in dogs with B-cell lymphoma

By Smith, P A D et al.·Published in Veterinary journal (London, England : 1997)·2020·School of Veterinary Medicine, United Kingdom·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: The prevalence and characterisation of TRAF3 and POT1 mutations in canine B-cell lymphoma.

Species:
dog

Plain-English summary

A group of dogs with B-cell lymphoma, a type of cancer affecting the immune system, was studied to understand the genetic mutations involved. Researchers found that about 36% of these dogs had harmful mutations in a gene called TRAF3, and 17% had mutations in another gene called POT1. These mutations were not present in dogs with other types of diseases, indicating they may play a significant role in the development of B-cell lymphoma. The findings suggest that these genetic changes could be important for future treatments and understanding the disease better.

People also search for: dog lymphoma symptoms · canine B-cell lymphoma treatment · TRAF3 mutations in dogs

Abstract

The genetic and mutational basis of canine lymphoma remains poorly understood. Several genes, including TRAF3 and POT1, are mutated in canine B-cell lymphoma (cBCL), and are likely involved in the pathogenesis of this disease. The purpose of this study was to assess the prevalence of TRAF3 and POT1 mutations in a cohort of dogs with cBCL, compared to dogs with non-cBCL diseases (including four dogs with T-cell lymphoma [cTCL]). Forty-nine dogs were included (n = 24 cBCL; n = 25 non-cBCL). Eleven dogs had matched non-tumour DNA assessed to determine if mutations were germline or somatic. All dogs had TRAF3 and POT1 assessed by Sanger sequencing. The prevalence of deleterious TRAF3 and POT1 mutations in cBCL was 36% and 17%, respectively. A deleterious TRAF3 mutation was suspected to be germline in 1/5 cases with matched non-tumour DNA available for comparison. Deleterious mutations were not found in specimens from the non-cBCL group. Several synonymous variants were identified in both genes in cBCL and non-cBCL samples, which likely represent polymorphisms. These results indicate TRAF3 and POT1 mutations are common in cBCL. Deleterious TRAF3 and POT1 mutations were only identified in dogs with cBCL, and not in dogs with non-cBCL diseases, suggesting they are important in the pathogenesis of cBCL. Future studies to investigate the prognostic and therapeutic implications of these mutations are required.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33323169/